CD274 and non-small cell lung carcinoma: We investigated whether the Glasgow prognostic score (GPS), neutrophil‐to‐lymphocyte ratio, and body mass index (BMI) can be used to evaluate the effect of first‐line pembrolizumab monotherapy in patients with advanced non‐small cell lung cancer (NSCLC) who express high levels of programmed death‐ligand 1 (PD‐L1).